# Lorazepam Effects on Neuroimaging Measures

> **NCT04671836** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Northwell Health**

## Conditions studied

- Lorazepam
- Neuroimaging

## Interventions

- **DRUG:** Lorazepam 1Mg Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04671836
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No longer interested in conducing study
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671836, "Lorazepam Effects on Neuroimaging Measures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04671836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*